KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 3,322 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 3,322 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $26.71, for a total value of $88,730.62. Following the completion of the sale, the chief executive officer owned 466,375 shares in the company, valued at approximately $12,456,876.25. This represents a 0.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Trading Up 0.3%

Shares of KALV stock traded up $0.07 during trading hours on Wednesday, reaching $26.80. The company’s stock had a trading volume of 2,280,060 shares, compared to its average volume of 2,219,124. The stock has a market capitalization of $1.37 billion, a P/E ratio of -6.78 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.85. The firm’s fifty day simple moving average is $19.76 and its 200 day simple moving average is $16.43. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. Finally, Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $30.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in shares of KalVista Pharmaceuticals by 45.8% in the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 589 shares during the period. SEB Asset Management AB purchased a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at approximately $7,072,000. Y Intercept Hong Kong Ltd purchased a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at approximately $680,000. Seven Fleet Capital Management LP purchased a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $782,000. Finally, Invesco Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 23.1% in the 4th quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 14,621 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.